%V 14
%P 1470-1481
%D 2018
%O Copyright © 2018 The Authors. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
%K Amyloid PET concordance, Amyloid-β (1–42), Biomarker validation, CSF biomarkers, Clinical progression, Cutoffs, Phosphorylated tau (pTau), Total tau (tTau)
%X INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS: Cutoffs for Elecsys amyloid-β1-42 (Aβ), total tau/Aβ(1-42), and phosphorylated tau/Aβ(1-42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. RESULTS: CSF total tau/Aβ(1-42) and phosphorylated tau/Aβ(1-42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%-90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes. DISCUSSION: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.
%A O Hansson
%A J Seibyl
%A E Stomrud
%A H Zetterberg
%A JQ Trojanowski
%A T Bittner
%A V Lifke
%A V Corradini
%A U Eichenlaub
%A R Batrla
%A K Buck
%A K Zink
%A C Rabe
%A K Blennow
%A LM Shaw
%A . Swedish BioFINDER study group
%A . Alzheimer's Disease Neuroimaging Initiative
%T CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
%J Alzheimer's & Dementia
%C United States
%N 11
%L discovery10051921